Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

TerminatedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions
Metastatic Breast Cancer
Interventions
DRUG

18F Fluoroestradiol Radiopharmaceutical with PET/CT

Administration of one dose of 18F FES for PET/CT imaging

Trial Locations (24)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

The New York Presbyterian Hospital-Columbia University Medical Center, New York

15213

Magee-Womens Hospital of UPMC, Pittsburgh

18102

St. Luke's University Health Network, Allentown

19104

University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia

22903

University of Virginia, Charlottesville

24014

Blue Ridge Cancer Care, Roanoke

27610

WakeMed, Cary

27705

Duke University, Durham

30322

Emory University, Atlanta

33606

Tampa General Hospital Cancer Institute, Tampa

45429

Kettering Health Cancer Center, Kettering

71104

MD Clinics, Shreveport

75204

Baylor Research Institute d/b/a Baylor Scott & White Research Institute, Dallas

86001

Northern Arizona Healthcare, Flagstaff

90033

University of Southern California, Los Angeles

90404

Providence Saint John's Health Center, Santa Monica

90703

TOI Clinical Research, Cerritos

90806

Long Beach Memorial Medical Center, Long Beach

91010

City of Hope Comprehensive Cancer Center, Duarte

91405

Valley Breast Care, Van Nuys

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

95128

PET/CT Imaging of San Jose, San Jose

98109

Fred Hutchinson Cancer Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Simbec-Orion Group

INDUSTRY

collaborator

Medpace, Inc.

INDUSTRY

collaborator

Zionexa

INDUSTRY

lead

GE Healthcare

INDUSTRY